View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Olfa Taamallah ... (+2)
  • Olfa Taamallah
  • Yan Derocles

ODDO : Long majors vs short LCC : le choix de 2026

Sur 2026, nous estimons que la dynamique sera plus favorable aux majors européennes tant sur le RASK (croissance plus modérée des capacités et meilleure orientation du réseau long-courrier en particulier transatlantique), que sur le CASK hors carburant aidé par des effets de base positifs. Nous relevons notre opinion à Surperformance sur Air France-KLM et Lufthansa et dégradons Ryanair en Neutre et Wizz Air en Sous-performance.

Olfa Taamallah ... (+2)
  • Olfa Taamallah
  • Yan Derocles

ODDO : Long legacy carriers vs short LCC: the choice for 2026

For 2026, we think that the trend will be more favourable to the European legacy carriers in terms of both RASK (more modest growth in capacity and a more positive trend on the long-haul network, particularly transatlantic) and CASK excluding fuel, aided by positive base effects. We have upgraded Air France-KLM and Lufthansa to Outperform, downgraded Ryanair to Neutral and Wizz Air to Underperform. A more favourable trend expected in 2026 for legacy carriers

Guy Sips ... (+10)
  • Guy Sips
  • Jacob Mekhael
  • Kristof Samoy
  • Livio Luyten
  • Lynn Hautekeete
  • Michiel Declercq
  • Thibault Leneeuw
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi

Dynamic Top Pick List Update February 2026: Removing ASMi; Adding UCB

After today's changes (ASMi out, UCB in), we maintain a balanced approach in our Dynamic Top Pick List, with a particular emphasis on value stocks that have been overlooked. Our defensive holdings are overweight, including real estate, which stands to benefit from lower interest rates. We remove ASMi from our Dynamic Top Pick List as the recent share price performance has driven the valuation meaningfully ahead of fundamentals. Since early December, FY27 diluted EPS expectations have risen by a...

Maxime Stranart ... (+3)
  • Maxime Stranart
  • Reg Watson
  • CFA

JDE Peet's/Kodiak Moment/HOLD

KDP and JDE Peet's have announced that Kodiak BidCo (the bid vehicle for KDP) is making a recommended public cash o?er for all issued and outstanding ordinary shares in the capital of JDE Peet's at a price of €31.85. We see limited catalysts for the share price and expect the bid to succeed given that regulatory and union approvals have been secured and the majority shareholders have made an irrevocable undertaking to tender their shares to Kodiak BidCo. Therefore, we increase our 12-month targe...

Olfa Taamallah ... (+2)
  • Olfa Taamallah
  • Yan Derocles
Olfa Taamallah ... (+2)
  • Olfa Taamallah
  • Yan Derocles
 PRESS RELEASE

JDE Peet’s launches Nature Transition Plan to advance regenerative agr...

JDE Peet’s launches Nature Transition Plan to advance regenerative agriculture and deforestation-free coffee supply chains PRESS RELEASE Amsterdam, January 29, 2026 JDE Peet’s (EURONEXT: JDEP), the world’s leading pure-play coffee company, today unveiled its Nature Transition Plan – ‘Grounded in Nature’ – a science-based roadmap to protect ecosystems, strengthen farmer resilience, and secure the long-term viability of coffee production. The publication of the plan makes JDE Peet’s the first food and beverage company in the world to launch a nature transition plan that is fully aligned wi...

Amadeus It Group S.A.: 1 director

A director at Amadeus It Group S.A. sold 30,000 shares at 61.446EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...

Argen X SE: 1 director

A director at Argen X SE sold after exercising options/sold 3,625 shares at 695.710EUR and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over t...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

D'Ieteren: PHE does nice mid-size M&A in Spain / Fastned: Beat on gross profit, organic growth lags, high cash burn / JDE Peet's: Caffè Americano / Semi equipment: TSMC puts capex where its mouth is / Theon International: Increasing Harder Digital's capacity.

Hilde Van Boxstael ... (+5)
  • Hilde Van Boxstael
  • Livio Luyten
  • Lynn Hautekeete
  • Michiel Declercq
  • Wim Lewi
 PRESS RELEASE

Keurig Dr Pepper Launches Offer for JDE Peet’s Shares

Keurig Dr Pepper Launches Offer for JDE Peet’s Shares BURLINGTON, Mass., FRISCO, Texas and AMSTERDAM, January 15, 2026 – This is a joint press release by Keurig Dr Pepper Inc., Kodiak BidCo B.V. and JDE Peet’s N.V. pursuant to the provisions of Article 10, paragraph 3 and Article 18, paragraph 3 of the Dutch Decree on public takeover bids (Besluit openbare biedingen Wft) (the “Decree”) in connection with the Offer (as defined below). This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities in JDE Peet’s N.V. Any offer will be mad...

Jacob Mekhael
  • Jacob Mekhael

argenx Vyvgart sBLA acceptance in seronegative gMG comes with priority...

argenx announced that the FDA has accepted for priority review a sBLA for Vyvgart IV for the treatment of adults with acetylcholine receptor antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG), with a PDUFA target action date of 10 May 2026. The sBLA acceptance and priority review for Vyvgart in seronegative gMG brings argenx a step closer to its aim of having the broadest possible label in this setting. argenx estimates the commercial opportunity for seronegative gMG could add 1...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch